According to AcelRx Pharmaceuticals 's latest financial reports the company's current earnings are C$0.65 Million. In 2022 the company made an earning of C$78.79 Million, an increase over its 2021 earnings that were of -C$48.02 Million. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -C$13.68 Million | -117.36% |
2022 | C$78.79 M | -264.1% |
2021 | -C$48.02 Million | -13.08% |
2020 | -C$55.25 Million | -24.16% |
2019 | -C$72.84 Million | 12.92% |
2018 | -C$64.51 Million | -9.7% |
2017 | -C$71.44 Million | 20.88% |
2016 | -C$59.1 Million | 82.71% |
2015 | -C$32.35 Million | -29.12% |
2014 | -C$45.64 Million | 42.38% |
2013 | -C$32.06 Million | -27.33% |
2012 | -C$44.11 Million | 66.59% |
2011 | -C$26.48 Million | 70.22% |
2010 | -C$15.56 Million |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
![]() Cara Therapeutics
CARA | -C$85.92 Million | 510.40% | ๐บ๐ธ USA |
![]() Recro Pharma
REPH | C$5.14 M | -136.59% | ๐บ๐ธ USA |